newsfilter
← Latest News
Business Wire·

Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

– Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer (UC) patients from MARIO-275 – – MARIO-3 triple negative breast cancer (TNBC) data update on track by year end – – Furth